Baudax BioInc Net Worth
Baudax BioInc Net Worth Breakdown | BXRX |
Baudax BioInc Net Worth Analysis
Baudax BioInc's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Baudax BioInc's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Baudax BioInc's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Baudax BioInc's net worth analysis. One common approach is to calculate Baudax BioInc's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Baudax BioInc's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Baudax BioInc's net worth. This approach calculates the present value of Baudax BioInc's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Baudax BioInc's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Baudax BioInc's net worth. This involves comparing Baudax BioInc's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Baudax BioInc's net worth relative to its peers.
Enterprise Value |
|
To determine if Baudax BioInc is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Baudax BioInc's net worth research are outlined below:
| Baudax BioInc generated a negative expected return over the last 90 days | |
| Baudax BioInc has high historical volatility and very poor performance | |
| Baudax BioInc has some characteristics of a very speculative penny stock | |
| Baudax BioInc has a very high chance of going through financial distress in the upcoming years | |
| The company currently holds 7.12 M in liabilities with Debt to Equity (D/E) ratio of 2.26, implying the company greatly relies on financing operations through barrowing. Baudax BioInc has a current ratio of 0.52, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Baudax BioInc until it has trouble settling it off, either with new capital or with free cash flow. So, Baudax BioInc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Baudax BioInc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Baudax to invest in growth at high rates of return. When we think about Baudax BioInc's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 1.27 M. Net Loss for the year was (7.15 M) with loss before overhead, payroll, taxes, and interest of (5.74 M). | |
| Baudax BioInc currently holds about 5.65 M in cash with (14.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Baudax BioInc has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of tradable shares by Kim Yong Chan of Baudax BioInc subject to Rule 16b-3 |
Baudax BioInc Quarterly Good Will |
|
Baudax BioInc uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Baudax BioInc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Baudax BioInc's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of November 2023 Upcoming Quarterly Report | View | |
| 22nd of February 2024 Next Financial Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of June 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Baudax BioInc's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Baudax BioInc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Baudax BioInc backward and forwards among themselves. Baudax BioInc's institutional investor refers to the entity that pools money to purchase Baudax BioInc's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Virtu Financial Llc | 2023-12-31 | 0.0 | Sittner & Nelson, Llc | 2023-09-30 | 0.0 | Blackrock Inc | 2023-12-31 | 0.0 | Advisor Group Holdings, Inc. | 2023-12-31 | 0.0 | Xtx Topco Ltd | 2023-12-31 | 0.0 | Creative Planning Inc | 2023-09-30 | 0.0 | State Street Corporation | 2023-12-31 | 0.0 | Susquehanna International Group, Llp | 2023-12-31 | 0.0 | Wells Fargo & Co | 2023-12-31 | 0.0 | Jane Street Group, Llc | 2023-09-30 | 0.0 | Tower Research Capital Llc | 2023-12-31 | 0.0 |
Follow Baudax BioInc's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 950.33 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Baudax BioInc's market, we take the total number of its shares issued and multiply it by Baudax BioInc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Project Baudax BioInc's profitablity
Baudax BioInc's profitability indicators refer to fundamental financial ratios that showcase Baudax BioInc's ability to generate income relative to its revenue or operating costs. If, let's say, Baudax BioInc is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Baudax BioInc's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Baudax BioInc's profitability requires more research than a typical breakdown of Baudax BioInc's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (6.69) | (7.03) | |
| Return On Capital Employed | 4.47 | 4.70 | |
| Return On Assets | (6.74) | (6.40) | |
| Return On Equity | 2.18 | 1.22 |
When accessing Baudax BioInc's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Baudax BioInc's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Baudax BioInc's profitability and make more informed investment decisions.
The data published in Baudax BioInc's official financial statements usually reflect Baudax BioInc's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Baudax BioInc. For example, before you start analyzing numbers published by Baudax accountants, it's critical to develop an understanding of what Baudax BioInc's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Baudax BioInc's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Baudax BioInc's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Baudax BioInc's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Baudax BioInc. Please utilize our Beneish M Score to check the likelihood of Baudax BioInc's management manipulating its earnings.
Evaluate Baudax BioInc's management efficiency
Baudax BioInc has return on total asset (ROA) of (1.1493) % which means that it has lost $1.1493 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (47.0421) %, meaning that it created substantial loss on money invested by shareholders. Baudax BioInc's management efficiency ratios could be used to measure how well Baudax BioInc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 4.70 in 2024, whereas Return On Tangible Assets are likely to drop (7.03) in 2024. At this time, Baudax BioInc's Intangible Assets are fairly stable compared to the past year. Debt To Assets is likely to rise to 0.67 in 2024, whereas Total Assets are likely to drop slightly above 8.6 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (65.79) | (69.08) | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | (71.57) | (75.14) | |
| Enterprise Value Over EBITDA | (0.21) | (0.22) | |
| Price Book Value Ratio | (0.04) | (0.04) | |
| Enterprise Value Multiple | (0.21) | (0.22) | |
| Price Fair Value | (0.04) | (0.04) | |
| Enterprise Value | 3.4 M | 3.2 M |
The analysis of Baudax BioInc's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Baudax BioInc's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Baudax Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 6.6339 | Revenue 1.3 M | Quarterly Revenue Growth (0.23) | Revenue Per Share 0.318 | Return On Equity (47.04) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Baudax BioInc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Baudax BioInc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Baudax BioInc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kim Yong Chan over three weeks ago Disposition of tradable shares by Kim Yong Chan of Baudax BioInc subject to Rule 16b-3 | ||
Altomari Alfred over a month ago Insider Trading | ||
Kim Yong Chan over six months ago Baudax BioInc exotic insider transaction detected |
Baudax BioInc Earnings per Share Projection vs Actual
Be your own money manager
Our tools can tell you how much better you can do entering a position in Baudax BioInc without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Share Portfolio Now
Share PortfolioTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Baudax BioInc Corporate Management
Elected by the shareholders, the Baudax BioInc's board of directors comprises two types of representatives: Baudax BioInc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Baudax. The board's role is to monitor Baudax BioInc's management team and ensure that shareholders' interests are well served. Baudax BioInc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Baudax BioInc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Natalie McAndrew | Consultant Officer | Profile | |
| Jillian Dilmore | Corp Controller | Profile | |
| Diane Myers | VP Quality | Profile | |
| Mike Choi | Vice Analysis | Profile |
How to buy Baudax Stock?
The net worth of Baudax BioInc is the difference between its total assets and liabilities. Baudax BioInc's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Baudax BioInc's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Baudax BioInc's net worth can be used as a measure of its financial health and stability which can help investors to decide if Baudax BioInc is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Baudax BioInc stock.Already Invested in Baudax BioInc?
The danger of trading Baudax BioInc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Baudax BioInc is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Baudax BioInc. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Baudax BioInc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Baudax BioInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Baudax BioInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Baudax Bioinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Baudax Bioinc Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Baudax BioInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Baudax Stock please use our How to Invest in Baudax BioInc guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Baudax Stock analysis
When running Baudax BioInc's price analysis, check to measure Baudax BioInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Baudax BioInc is operating at the current time. Most of Baudax BioInc's value examination focuses on studying past and present price action to predict the probability of Baudax BioInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Baudax BioInc's price. Additionally, you may evaluate how the addition of Baudax BioInc to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Baudax BioInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Baudax BioInc. If investors know Baudax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Baudax BioInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (94.13) | Revenue Per Share 0.318 | Quarterly Revenue Growth (0.23) | Return On Assets (1.15) | Return On Equity (47.04) |
The market value of Baudax BioInc is measured differently than its book value, which is the value of Baudax that is recorded on the company's balance sheet. Investors also form their own opinion of Baudax BioInc's value that differs from its market value or its book value, called intrinsic value, which is Baudax BioInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Baudax BioInc's market value can be influenced by many factors that don't directly affect Baudax BioInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Baudax BioInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Baudax BioInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Baudax BioInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.